Arrevus’s focus is to develop population-specific therapies that will reduce treatment failure rates and improve clinical outcomes for these targeted groups.
There is an urgent need to provide effective treatment options for patients who are unable to mount a normal immune response to bacterial infections, due to underlying diseases. This population is at high risk of poor outcomes from these infections, ranging from antibiotic switching to increased mortality. Arrevus follows three principals in developing solutions to this problem:
Utilize nature as a guide for unique drug development
Focus on immunocompromised patient populations that suffer from serious infections
Optimize trial design